EUVIMEDEUVIMED entdecken
Open Access

Genome-Derived Ampullary Adenocarcinoma Classifier and Postresection Prognostication

Brett L Ecker, Kenneth Seier, Austin M Eckhoff, Gabriella N Tortorello, Peter J Allen, Vinod P Balachandran, Nicola Blackburn, Michael I D'Angelica, Ronald P DeMatteo, Daniel G Blazer, Jeffrey A Drebin, William E Fisher und 18 weitere

JAMA Surgery · 2024

DOI: 10.1001/jamasurg.2024.3588 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Surgery, 2024. Verfasst von Brett L Ecker und 29 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, Rutgers Cancer Institute, New Brunswick, New Jersey. Hauptthemen laut MEDLINE: Adenocarcinoma, Ampulla of Vater, Common Bile Duct Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Ampullary adenocarcinoma (AA) is characterized by clinical and genomic heterogeneity. A previously developed genomic classifier defined biologically distinct phenotypes with greater accuracy than standard histologic classification. External validation is needed before routine clinical use.

Objective

To test external validity of the prognostic value of the hidden genome classifier of AA. Design, Setting, and Participants This retrospective cohort study took place at 6 international academic institutions. Consecutive patients (n = 192) who underwent curative-intent resection of histologically confirmed AA were included. The data were analyzed from January 2005 through July 2020. Exposures The multilevel meta-feature regression model previously trained on a prospectively sequenced cohort of 3411 patients (1001 pancreatic adenocarcinoma, 165 distal bile duct adenocarcinoma, and 2245 colorectal adenocarcinoma) was applied to AA sequencing data to quantify the relative proportions of parental cell of origin. Main Outcome and Measures Genomic classification was correlated with immunohistologic subtype (intestinal [INT] or pancreatobiliary [PB]) and with overall survival (OS), using the log-rank test and Cox proportional hazard models.

Results

Among 192 patients with AA (median age, 69.0 [IQR, 60.0-74.0] years and 134 were male [64%]), concordance between immunohistologic and genomic subtypes was 55%. Most INT subtype tumors were categorized into the colorectal genomic subtype (43 of 57 [72.9%]). Of the 114 PB subtype tumors, 29 had a pancreatic genomic profile (25.4%) and 24 had a distal bile duct genomic profile (21.1%). Whereas the standard immunohistologic subtypes were not associated with survival (log rank P = .26), predicted genomic probabilities were correlated with survival probability. Genomic scores with higher colorectal probability were associated with higher survival probability; higher pancreatic and distal bile duct probabilities were associated with lower survival probability. Conclusions and Relevance The AA genomic classifier is reproducible with available molecular testing in a diverse international cohort of patients and improves stratification of the divergent clinical outcomes beyond standard immunohistologic classification. These data provide a molecular classification that may be incorporated into clinical trials for prospective validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaAmpulla of VaterCommon Bile Duct NeoplasmsAgedFemaleHumansMaleMiddle AgedColorectal NeoplasmsGenomicsPancreatic NeoplasmsPrognosisRetrospective Studies

Autor:innen und Institutionen

  • Division of Surgical Oncology, Rutgers Cancer Institute, New Brunswick, New Jersey.
  • Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Surgery, Duke University School of Medicine, Durham, North Carolina.
  • Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria Street, Darlinghurst, Sydney, New South Wales, Australia.

Förderung

  • NCI NIH HHS

Zitieren

APA

Ecker, B. L., Seier, K., Eckhoff, A. M., Tortorello, G. N., Allen, P. J., Balachandran, V. P., Blackburn, N., D'Angelica, M. I., DeMatteo, R. P., Blazer, D. G., Drebin, J. A., Fisher, W. E., Fortuna, D., Gill, A. J., Gingras, M. C., Kingham, T. P., Lee, M. K., Lidsky, M. E., Nussbaum, D. P., …, & Jarnagin, W. R. (2024). Genome-Derived Ampullary Adenocarcinoma Classifier and Postresection Prognostication. JAMA Surgery. https://doi.org/10.1001/jamasurg.2024.3588

Vancouver

Ecker BL, Seier K, Eckhoff AM, Tortorello GN, Allen PJ, Balachandran VP, et al. Genome-Derived Ampullary Adenocarcinoma Classifier and Postresection Prognostication. JAMA Surgery. 2024. doi:10.1001/jamasurg.2024.3588

BibTeX
@article{Ecker2024,
  author = {Ecker, Brett L and Seier, Kenneth and Eckhoff, Austin M and Tortorello, Gabriella N and Allen, Peter J and Balachandran, Vinod P and Blackburn, Nicola and D'Angelica, Michael I and DeMatteo, Ronald P and Blazer, Daniel G and Drebin, Jeffrey A and Fisher, William E and Fortuna, Danielle and Gill, Anthony J and Gingras, Marie-Claude and Kingham, T Peter and Lee, Major K and Lidsky, Michael E and Nussbaum, Daniel P and Overman, Michael J and Samra, Jaswinder S and Shen, Ronglai and Sigel, Carlie S and Soares, Kevin C and Vollmer, Charles M and Wei, Alice C and Zani, Sabino and Roses, Robert E and Gonen, Mithat and Jarnagin, William R},
  title = {Genome-Derived Ampullary Adenocarcinoma Classifier and Postresection Prognostication},
  journal = {JAMA Surgery},
  year = {2024},
  doi = {10.1001/jamasurg.2024.3588}
}
Kostenlos starten →